A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition to continue immunotherapy treatment for the first time.

There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away ...

Via Christi is the first hospital in the region to perform a new procedure for atrial fibrillation for patients who can’t ...

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

FineHeart, a clinical-stage MedTech company developing innovative medical devices for heart failure, has achieved a major milestone in its ...